Heart failure (HF), a complex clinical syndrome characterised by the reduced ability of the heart to pump and/or fill with blood, is a global pandemic and is increasing in prevalence. HF health expenditures are considerable and will increase dramatically with an ageing population. Despite the significant advances in therapies and prevention, mortality and morbidity are still high and quality of life poor for heart failure patients.

ACE inhibitors have been shown to reduce the risk of death and hospital admission in patients with HF and reduced ejection fraction [Image: Shutterstock].

Please sign in to read more